From 02a9500ba99424317db9dad9c3efd4c1ed3c5a87 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 05:46:23 +0000 Subject: [PATCH 1/2] extract: 2026-03-30-jacc-cvd-mortality-trends-1999-2023 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...as four independent methodologies confirm.md | 6 ++++++ ...vailability-is-not-the-binding-constraint.md | 6 ++++++ ...g-access-mediated-pharmacological-ceiling.md | 6 ++++++ ...03-30-jacc-cvd-mortality-trends-1999-2023.md | 17 ++++++++++++++++- 4 files changed, 34 insertions(+), 1 deletion(-) diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index 5ff551fb9..8b800acc4 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -72,6 +72,12 @@ Amodei's complementary factors framework explicitly identifies 'human constraint PNAS 2026 attributes US life expectancy stagnation to 'a complex convergence of rising chronic disease, shifting behavioral risks, and increases in certain cancers among younger adults' — explicitly identifying behavioral and social factors as the drivers of cohort-level mortality deterioration, not medical care quality. +### Additional Evidence (confirm) +*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30* + +Hypertension-related CVD mortality doubled 2000-2023 (23→43 per 100,000) despite widespread availability of effective, cheap generic antihypertensives. This is the strongest single empirical case for the 80-90% non-clinical determinants thesis because the failure occurs despite pharmacological solutions being universally accessible, proving the constraint is behavioral/SDOH not medical. + + Relevant Notes: - [[social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem]] -- loneliness is one of the most actionable SDOH factors with clear cost signature and robust evidence diff --git a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md index f324b9f76..1834536e3 100644 --- a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md +++ b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md @@ -19,6 +19,12 @@ The JACC study tracking 1999-2023 NHANES data reveals a striking failure mode in --- +### Additional Evidence (extend) +*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30* + +The population-level outcome of poor blood pressure control manifests as doubled hypertensive disease mortality 2000-2023, with 664,000 deaths in 2023 where hypertension was primary or contributing cause. Middle-aged adults (35-64) showed the most pronounced increases, indicating the treatment failure compounds over working-age years. + + Relevant Notes: - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] - [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] diff --git a/domains/health/pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md b/domains/health/pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md index a17fe2fc4..adc0496bd 100644 --- a/domains/health/pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md +++ b/domains/health/pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md @@ -30,6 +30,12 @@ This is direct quantitative evidence that the 'pharmacological ceiling' in US ca Large US claims database (2015-2021) shows PCSK9 penetration rose from 0.05% in Q3 2015 to only 2.5% by Q2 2019 — four years post-FDA approval. Overall penetration: 0.9% of ASCVD patients on statin therapy filled a PCSK9 prescription (126,419 patients). Only 49.93% of written PCSK9 prescriptions were successfully filled (vs 68-84% for comparable branded cardiometabolic therapies). Hospitalized ASCVD patients (2020-2022) received PCSK9 inhibitors at only 1.3% rate despite hospitalization providing ideal prescribing opportunity. Commercial insurance rejection: 69.5%; Medicare: 42.3%. The 2018 price reduction (from ~$14,000/year to ~$5,800/year) improved adherence in commercially insured patients but did NOT produce population-level penetration increase. +### Additional Evidence (extend) +*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30* + +The CVD stagnation mechanism has three distinct layers: (1) pharmacological saturation where statins succeeded in reducing ischemic disease, (2) access-mediated ceilings where PCSK9 inhibitors cannot reach patients despite efficacy, and (3) behavioral/SDOH treatment failure where hypertensive disease mortality doubled despite cheap, accessible medications. This third layer was previously missing from the CVD stagnation hypothesis. + + Relevant Notes: - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] diff --git a/inbox/queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md b/inbox/queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md index 36e9ac775..0d5c48195 100644 --- a/inbox/queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md +++ b/inbox/queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md @@ -7,9 +7,13 @@ date: 2025-06-01 domain: health secondary_domains: [] format: journal-article -status: unprocessed +status: enrichment priority: high tags: [CVD-mortality, hypertension, ischemic-heart-disease, trends, United-States, JACC, 2023, age-standardized, midlife] +processed_by: vida +processed_date: 2026-03-30 +enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -62,3 +66,14 @@ These two trajectories coexisting reveals that the pharmacological ceiling story PRIMARY CONNECTION: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]] — parallel structural failure WHY ARCHIVED: The hypertension mortality doubling is the third layer of the CVD stagnation argument that was previously missing from the KB. It also directly evidences Belief 2 (80-90% non-clinical) because the failure occurs despite widely available, cheap, effective drugs. EXTRACTION HINT: Extract as a claim about hypertension-specific mortality trends, distinct from the general "US CVD stagnation" claim. The key argumentative move is: ischemic disease improved (medicine worked) + hypertensive disease doubled (medicine failed despite availability) = the failure is behavioral/SDOH, not pharmacological. This is the strongest direct evidence for Belief 2 in the health domain. + + +## Key Facts +- Ischemic heart disease age-standardized mortality rate declined 1999-2023 in the United States +- Hypertensive disease contributed to approximately 664,000 deaths in 2023 as primary or contributing cause +- Cardiomyopathy mortality declined 1999-2023 +- Arrhythmia mortality increased 1999-2023 +- Pulmonary heart disease mortality increased 1999-2023 +- CVD accounted for 915,973 deaths in 2023 with US age-adjusted mortality rate of 218.3 per 100,000 +- 2022 CVD AAMR (434.6) remains higher than pre-pandemic 2019 levels +- 190,661 excess CVD deaths occurred 2020-2022 -- 2.45.2 From 3d2158d9c6b718887f2c643315665795ac0b6108 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 05:47:12 +0000 Subject: [PATCH 2/2] auto-fix: strip 7 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...te as four independent methodologies confirm.md | 14 +++++++------- 1 file changed, 7 insertions(+), 7 deletions(-) diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index 8b800acc4..a358105f7 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -31,44 +31,44 @@ This has structural implications for how healthcare should be organized. Since [ ### Additional Evidence (confirm) -*Source: [[2024-09-19-commonwealth-fund-mirror-mirror-2024]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-09-19-commonwealth-fund-mirror-mirror-2024 | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the strongest real-world proof of this claim. The US ranks **second in care process quality** (clinical excellence when care is accessed) but **last in health outcomes** (life expectancy, avoidable deaths) among 10 peer nations. This paradox proves that clinical quality alone cannot produce population health — the US has near-best clinical care AND worst outcomes, demonstrating that non-clinical factors (access, equity, social determinants) dominate outcome determination. The care process vs. outcomes decoupling across 70 measures and nearly 75% patient/physician-reported data is the international benchmark showing medical care's limited contribution to population health outcomes. ### Additional Evidence (extend) -*Source: [[2025-00-00-nhs-england-waiting-times-underfunding]] | Added: 2026-03-15* +*Source: 2025-00-00-nhs-england-waiting-times-underfunding | Added: 2026-03-15* The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes. ### Additional Evidence (confirm) -*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* +*Source: 2025-12-01-who-glp1-global-guidelines-obesity | Added: 2026-03-16* WHO's three-pillar framework for GLP-1 obesity treatment explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment.' This institutional positioning from the global health authority confirms that pharmaceutical intervention alone cannot address health outcomes driven by behavioral and social factors. ### Additional Evidence (extend) -*Source: [[2025-04-07-tufts-health-affairs-medically-tailored-meals-50-states]] | Added: 2026-03-18* +*Source: 2025-04-07-tufts-health-affairs-medically-tailored-meals-50-states | Added: 2026-03-18* While social determinants predict health outcomes in observational studies, RCT evidence from food-as-medicine interventions shows that directly addressing social determinants (food insecurity) does not automatically improve clinical outcomes. The AHA 2025 systematic review of 14 US RCTs found Food Is Medicine programs improve diet quality and food security but "impact on clinical outcomes was inconsistent and often failed to reach statistical significance." This suggests the causal pathway from social determinants to health is more complex than simple resource provision. ### Additional Evidence (extend) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-18* +*Source: 2025-01-01-produce-prescriptions-diabetes-care-critique | Added: 2026-03-18* The Diabetes Care perspective provides a specific mechanism example: produce prescription programs may improve food security (a social determinant) without improving clinical outcomes (HbA1c, diabetes control) because the causal pathway from social disadvantage to disease is not reversible through single-factor interventions. This demonstrates the 10-20% medical care contribution in practice—addressing one SDOH factor (food access) doesn't overcome the compound effects of poverty, stress, and social disadvantage. ### Additional Evidence (confirm) -*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19* +*Source: 2026-03-19-vida-ai-biology-acceleration-healthspan-constraint | Added: 2026-03-19* Amodei's complementary factors framework explicitly identifies 'human constraints' (behavior change, social systems, meaning-making) as a factor that bounds AI returns even in biological science. This provides theoretical grounding for why the 80-90% non-clinical determinants remain unaddressed by AI-accelerated biology—they fall into the 'human constraints' category that AI cannot optimize. --- ### Additional Evidence (confirm) -*Source: [[2026-03-10-abrams-bramajo-pnas-birth-cohort-mortality-us-life-expectancy]] | Added: 2026-03-24* +*Source: 2026-03-10-abrams-bramajo-pnas-birth-cohort-mortality-us-life-expectancy | Added: 2026-03-24* PNAS 2026 attributes US life expectancy stagnation to 'a complex convergence of rising chronic disease, shifting behavioral risks, and increases in certain cancers among younger adults' — explicitly identifying behavioral and social factors as the drivers of cohort-level mortality deterioration, not medical care quality. -- 2.45.2